Total trials
281
Active
59
Phase 3
5
Total enrollment
578,656
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Monalizumab | — | — | — | — | — | 1 | |
| Loncastuximab Tesirine | — | — | — | — | — | 1 | |
| androgen deprivation therapy | — | — | — | — | — | 1 | |
| immune evaluation | — | — | — | — | — | 1 |
Next readouts
- 2025-03-01
- 2025-03-04
- 2026-07
Top conditions
- Colorectal Cancer8
- Lung Cancer7
- Infertility7
- Breast Cancer5
- Surgery5
- Bladder Cancer5
- ART5
- Pancreatic Cancer5
Frequently asked questions about Istituto Clinico Humanitas
- How many clinical trials does Istituto Clinico Humanitas have on ClinicalTrials.gov?
- Istituto Clinico Humanitas is listed as the lead sponsor on 281 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Istituto Clinico Humanitas's trials are in Phase 3?
- 5 of Istituto Clinico Humanitas's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Istituto Clinico Humanitas focus on?
- Istituto Clinico Humanitas's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Lung Cancer, Infertility, Breast Cancer, Surgery.
- When are Istituto Clinico Humanitas's next clinical trial readouts?
- Istituto Clinico Humanitas has 3 upcoming primary-completion readouts tracked here; the soonest is “Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation”, expected around 2025-03-01.